Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 2/20 | 0.52 |
| ▸ | CD22 | P20273 | 13/20 | 0.39 |
| ▸ | MAG | P20916 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14752226 | 0.92 | NANP (0.43) | NANPCD22MAG | |
| SCHEMBL15677307 | 0.89 | NANP (0.51) | NANPCD22MAG | |
| SCHEMBL12991357 | 0.88 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL23188762 | 0.88 | NANP (0.54) | NANPCD22MAG | |
| SCHEMBL17722651 | 0.83 | NANP (0.63) | NANPCD22MAG | |
| SCHEMBL17000127 | 0.83 | NANP (0.63) | NANPCD22MAG | |
| SCHEMBL14454528 | 0.83 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL12730475 | 0.83 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL12341443 | 0.83 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL15321632 | 0.82 | NANP (0.61) | NANPCD22MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874714-B2 | Method of treating fibroblast growth factor 21 (FGF-21) deficiency | 89BIO LTD. (IL) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874714-B2 | Method of treating fibroblast growth factor 21 (FGF-21) deficiency | FGF2, FGF1, FGFR1 | NANP 212/4885CD22 617/4885MAG 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.